Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046

NCT04195698 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04195698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04195698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
January 15, 2020
Completion date
September 11, 2023
Enrollment
475 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis